FDA’s Streamlined Review Pilot Takes Flight; Second Oncology sNDA Through Process
This article was originally published in RPM Report
FDA’s Office of Hematology & Oncology Products will complete four to five streamlined reviews of supplemental oncology indications before reflecting on the “lessons learned” from the pilot program. After the successful review of Genentech’s Avastin for cervical cancer, FDA says that a second application has gone through the abbreviated process.
You may also be interested in...
US FDA commissioner outlines plans to allow partial submissions as soon as database locks and to create joint sponsor-agency review documents.
Unprecedented wave of cancer immunotherapies is in some ways a mirror image of AIDS crisis as FDA explores new tools to accelerate drug development, including modeling techniques and statistical approaches to efficacy. It's an effort to encourage a regulatory revolution in response to a massive number of products in development as opposed to the AIDS-era effort to get products studied.
Instead of waiting until after regulatory events like COVID boosters and Aduhelm, FDA should describe its decision-making process along the way to help restore public faith in the agency, former deputy commissioner Josh Sharfstein says.